Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: a test-negative design study

Hannah Chung, Siyi He, View ORCID ProfileSharifa Nasreen, Maria E. Sundaram, Sarah A. Buchan, Sarah E. Wilson, Branson Chen, Andrew Calzavara, Deshayne B. Fell, Peter C. Austin, Kumanan Wilson, Kevin L. Schwartz, Kevin A. Brown, Jonathan B. Gubbay, Nicole E. Basta, Salaheddin M. Mahmud, Christiaan H. Righolt, View ORCID ProfileLawrence W. Svenson, View ORCID ProfileShannon E. MacDonald, Naveed Z. Janjua, Mina Tadrous, Jeffrey C. Kwong
doi: https://doi.org/10.1101/2021.05.24.21257744
Hannah Chung
1ICES, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siyi He
1ICES, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharifa Nasreen
1ICES, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sharifa Nasreen
Maria E. Sundaram
1ICES, Toronto, ON
2Dalla Lana School of Public Health, University of Toronto, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah A. Buchan
1ICES, Toronto, ON
2Dalla Lana School of Public Health, University of Toronto, Toronto, ON
3Public Health Ontario, ON
4Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah E. Wilson
1ICES, Toronto, ON
2Dalla Lana School of Public Health, University of Toronto, Toronto, ON
3Public Health Ontario, ON
4Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Branson Chen
1ICES, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Calzavara
1ICES, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deshayne B. Fell
1ICES, Toronto, ON
5School of Epidemiology and Public Health, University of Ottawa, ON
6Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter C. Austin
1ICES, Toronto, ON
7Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kumanan Wilson
8Department of Medicine, University of Ottawa, Ottawa and Bruyere Hospital Research Institutes, Ottawa, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin L. Schwartz
1ICES, Toronto, ON
2Dalla Lana School of Public Health, University of Toronto, Toronto, ON
3Public Health Ontario, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin A. Brown
1ICES, Toronto, ON
2Dalla Lana School of Public Health, University of Toronto, Toronto, ON
3Public Health Ontario, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan B. Gubbay
3Public Health Ontario, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole E. Basta
9Department of Epidemiology, Biostatistics, and Occupational Health, School of Population and Global Health, McGill University, Montreal, QC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salaheddin M. Mahmud
10Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, Winnipeg, MB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiaan H. Righolt
10Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, Winnipeg, MB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence W. Svenson
11Analytics and Performance Reporting Branch, Alberta Health, Edmonton, AB
12Division of Preventive Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB
13School of Public Health, University of Alberta, Edmonton, AB
14Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lawrence W. Svenson
Shannon E. MacDonald
13School of Public Health, University of Alberta, Edmonton, AB
15Faculty of Nursing, University of Alberta, Edmonton, AB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shannon E. MacDonald
Naveed Z. Janjua
16British Columbia Centre for Disease Control, Vancouver, BC
17School of Population and Public Health, University of British Columbia, Vancouver, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mina Tadrous
1ICES, Toronto, ON
18Women’s College Hospital, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey C. Kwong
1ICES, Toronto, ON
2Dalla Lana School of Public Health, University of Toronto, Toronto, ON
3Public Health Ontario, ON
4Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, ON
19Department of Family and Community Medicine, University of Toronto, Toronto, ON
20University Health Network, Toronto, ON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jeff.kwong@utoronto.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objectives To estimate the effectiveness of mRNA COVID-19 vaccines against symptomatic infection and severe outcomes.

Design We applied a test-negative design study to linked laboratory, vaccination, and health administrative databases, and used multivariable logistic regression adjusting for demographic and clinical characteristics associated with SARS-CoV-2 and vaccine receipt to estimate vaccine effectiveness (VE) against symptomatic infection and severe outcomes.

Setting Ontario, Canada between 14 December 2020 and 19 April 2021.

Participants Community-dwelling adults aged ≥16 years who had COVID-19 symptoms and were tested for SARS-CoV-2.

Interventions Pfizer-BioNTech’s BNT162b2 or Moderna’s mRNA-1273 vaccine.

Main outcome measures Laboratory-confirmed SARS-CoV-2 by RT-PCR; hospitalization/death associated with SARS-CoV-2 infection.

Results Among 324,033 symptomatic individuals, 53,270 (16.4%) were positive for SARS-CoV-2 and 21,272 (6.6%) received ≥1 vaccine dose. Among test-positive cases, 2,479 (4.7%) had a severe outcome. VE against symptomatic infection ≥14 days after receiving only 1 dose was 60% (95%CI, 57 to 64%), increasing from 48% (95%CI, 41 to 54%) at 14–20 days after the first dose to 71% (95%CI, 63 to 78%) at 35–41 days. VE ≥7 days after 2 doses was 91% (95%CI, 89 to 93%). Against severe outcomes, VE ≥14 days after 1 dose was 70% (95%CI, 60 to 77%), increasing from 62% (95%CI, 44 to 75%) at 14–20 days to 91% (95%CI, 73 to 97%) at ≥35 days, whereas VE ≥7 days after 2 doses was 98% (95%CI, 88 to 100%). For adults aged ≥70 years, VE estimates were lower for intervals shortly after receiving 1 dose, but were comparable to younger adults for all intervals after 28 days. After 2 doses, we observed high VE against E484K-positive variants.

Conclusions Two doses of mRNA COVID-19 vaccines are highly effective against symptomatic infection and severe outcomes. Single-dose effectiveness is lower, particularly for older adults shortly after the first dose.

Competing Interest Statement

KW is CEO of CANImmunize and serves on the data safety board for the Medicago COVID-19 vaccine trial. SMM has received unrestricted research grants from Merck, GlaxoSmithKline, Sanofi Pasteur, Pfizer, and Roche-Assurex for unrelated studies. SMM has received fees as an advisory board member for GlaxoSmithKline, Merck, Pfizer, Sanofi Pasteur, and Seqirus. CHR has received an unrestricted research grant from Pfizer for an unrelated study. The other authors declare no conflicts of interest.

Funding Statement

This work was supported by the Canadian Immunization Research Network (CIRN) through a grant from the Public Health Agency of Canada and the Canadian Institutes of Health Research (CNF 151944). This project was also supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force. This study was also supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH). JCK is supported by Clinician-Scientist Award from the University of Toronto Department of Family and Community Medicine. PCA is supported by a Mid-Career Investigator Award from the Heart and Stroke Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

ICES is a prescribed entity under Ontario's Personal Health Information Protection Act (PHIPA). Section 45 of PHIPA authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Projects that use data collected by ICES under section 45 of PHIPA, and use no other data, are exempt from REB review. The use of the data in this project is authorized under section 45 and approved by ICES' Privacy and Legal Office.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Updated abstract; updated methods to clarify settings, definitions, and to add sensitivity analyses and additional analyses; updated results and discussion; supplemental materials updated.

Data Availability

The dataset from this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (e.g., healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email: das{at}ices.on.ca). The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely upon coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 26, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: a test-negative design study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: a test-negative design study
Hannah Chung, Siyi He, Sharifa Nasreen, Maria E. Sundaram, Sarah A. Buchan, Sarah E. Wilson, Branson Chen, Andrew Calzavara, Deshayne B. Fell, Peter C. Austin, Kumanan Wilson, Kevin L. Schwartz, Kevin A. Brown, Jonathan B. Gubbay, Nicole E. Basta, Salaheddin M. Mahmud, Christiaan H. Righolt, Lawrence W. Svenson, Shannon E. MacDonald, Naveed Z. Janjua, Mina Tadrous, Jeffrey C. Kwong
medRxiv 2021.05.24.21257744; doi: https://doi.org/10.1101/2021.05.24.21257744
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: a test-negative design study
Hannah Chung, Siyi He, Sharifa Nasreen, Maria E. Sundaram, Sarah A. Buchan, Sarah E. Wilson, Branson Chen, Andrew Calzavara, Deshayne B. Fell, Peter C. Austin, Kumanan Wilson, Kevin L. Schwartz, Kevin A. Brown, Jonathan B. Gubbay, Nicole E. Basta, Salaheddin M. Mahmud, Christiaan H. Righolt, Lawrence W. Svenson, Shannon E. MacDonald, Naveed Z. Janjua, Mina Tadrous, Jeffrey C. Kwong
medRxiv 2021.05.24.21257744; doi: https://doi.org/10.1101/2021.05.24.21257744

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (164)
  • Allergy and Immunology (416)
  • Anesthesia (92)
  • Cardiovascular Medicine (867)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (397)
  • Epidemiology (8589)
  • Forensic Medicine (4)
  • Gastroenterology (390)
  • Genetic and Genomic Medicine (1772)
  • Geriatric Medicine (169)
  • Health Economics (375)
  • Health Informatics (1252)
  • Health Policy (625)
  • Health Systems and Quality Improvement (472)
  • Hematology (197)
  • HIV/AIDS (380)
  • Infectious Diseases (except HIV/AIDS) (10344)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (193)
  • Medical Ethics (51)
  • Nephrology (214)
  • Neurology (1692)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (330)
  • Occupational and Environmental Health (451)
  • Oncology (933)
  • Ophthalmology (265)
  • Orthopedics (104)
  • Otolaryngology (172)
  • Pain Medicine (115)
  • Palliative Medicine (40)
  • Pathology (255)
  • Pediatrics (539)
  • Pharmacology and Therapeutics (257)
  • Primary Care Research (210)
  • Psychiatry and Clinical Psychology (1785)
  • Public and Global Health (3871)
  • Radiology and Imaging (627)
  • Rehabilitation Medicine and Physical Therapy (322)
  • Respiratory Medicine (525)
  • Rheumatology (208)
  • Sexual and Reproductive Health (170)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)